Cambridge University Oncology Society

368 posts

Cambridge University Oncology Society banner
Cambridge University Oncology Society

Cambridge University Oncology Society

@CUOncSoc

Cambridge University Oncology Society | Run by medical students | Check out our upcoming events below!

Cambridge, UK Katılım Aralık 2019
139 Takip Edilen223 Takipçiler
Cambridge University Oncology Society
Dr Raj Jena (@ml4cancer) is a group leader in machine learning and radiomics in the Department of Oncology and an honorary consultant in neuro-oncology at Addenbrooke's Hospital. He leads the AI/ML workstream of the £8.2 million CRUK funded RadNet research programme
English
0
0
2
93
Cambridge University Oncology Society
CONFERENCE POSTER & ORAL PRESENTATIONS DEADLINE EXTENDED- if you would like to present your Oncology-related research in our conference, please submit your abstract using the google form forms.gle/1aEEGbwsk2ScNd… NEW Deadline for submission is 15th January 2024!
Cambridge University Oncology Society tweet media
English
1
0
2
210
Cambridge University Oncology Society
CONFERENCE POSTER & ORAL PRESENTATIONS DEADLINE EXTENDED- if you would like to present your Oncology-related research in our conference, please submit your abstract using the google form forms.gle/1aEEGbwsk2ScNd… Deadline for submission is in 2 days (15th January 2024!)
Cambridge University Oncology Society tweet media
English
0
0
0
104
Cambridge University Oncology Society
As a urological surgeon, Grant has a specific interest in optimising the management of patients with initially localised renal cancer, by the development of early detection and optimal peri-surgical management.
English
0
0
0
99
Cambridge University Oncology Society
Grant Stewart is the Professor of Surgical Oncology and Honorary Consultant Urological Surgeon at Addenbrooke's Hospital. He is also the Director of the Academic Clinical Fellow Programme in Cambridge.
English
1
0
0
125
Cambridge University Oncology Society
@ICR_London @Chemical_probes Prof Workman is renowned for his research in molecularly targeted cancer drugs. Of note, Paul has been instrumental in the discovery of two approved drugs: the EGFR inhibitor gefitinib for lung cancer and the AKT inhibitor capivasertib for breast cancer.
English
1
0
2
191